17:
96:
Munder, PG; Modolell M; Adreesen R; Weltzien HU; Westphal O (1979). "Lysophosphatidylcholine (Lysolecithin) and its
Synthetic Analogues. Immunemodulating and Other Biologic Effects".
179:
van
Blitterswijk, W; Verheij M (2008). "Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects".
220:
36:
39:(LPCs), also called lysolecithins. They are synthesized by replacing the acyl-group within the LPC with an
54:
effects. Their anti-tumor effects are due to modulation of intracellular signalling pathways, inducing
161:
113:
32:
196:
153:
51:
188:
145:
105:
71:
225:
24:, an alkyl-lysophospholipid being studied for its potential use as a pharmaceutical drug
47:
136:
Houlihan, W; Lohmeyer M; Workman P; Cheon SH (1995). "Phospholipid antitumor agents".
214:
117:
165:
63:
40:
192:
67:
59:
21:
58:. It is highly selective, sparing healthy cells. Several examples including
55:
200:
149:
157:
109:
16:
15:
43:. In contrast to LPCs, ALPs are metabolically very stable.
131:
129:
127:
91:
89:
87:
8:
74:as drugs against cancer and other diseases.
46:ALPs are being studied for their potential
83:
7:
98:Springer Seminars in Immunopathology
14:
1:
181:Current Pharmaceutical Design
242:
193:10.2174/138161208785294636
138:Medicinal Research Reviews
221:Experimental cancer drugs
37:lysophosphatidylcholines
150:10.1002/med.2610150302
29:Alky-lysophospholipids
25:
20:Chemical structure of
31:(ALPs) are synthetic
19:
110:10.1007/BF01891668
50:(anti-cancer) and
26:
52:immune-modulating
233:
205:
204:
176:
170:
169:
133:
122:
121:
93:
241:
240:
236:
235:
234:
232:
231:
230:
211:
210:
209:
208:
187:(21): 2061–74.
178:
177:
173:
135:
134:
125:
95:
94:
85:
80:
12:
11:
5:
239:
237:
229:
228:
223:
213:
212:
207:
206:
171:
144:(3): 157–223.
123:
104:(2): 187–203.
82:
81:
79:
76:
48:antineoplastic
13:
10:
9:
6:
4:
3:
2:
238:
227:
224:
222:
219:
218:
216:
202:
198:
194:
190:
186:
182:
175:
172:
167:
163:
159:
155:
151:
147:
143:
139:
132:
130:
128:
124:
119:
115:
111:
107:
103:
99:
92:
90:
88:
84:
77:
75:
73:
69:
65:
61:
57:
53:
49:
44:
42:
38:
34:
30:
23:
18:
184:
180:
174:
141:
137:
101:
97:
45:
28:
27:
72:development
64:miltefosine
41:alkyl group
215:Categories
78:References
70:are under
68:perifosine
60:edelfosine
22:edelfosine
56:apoptosis
201:18691116
118:42907729
166:6997551
158:7658750
33:analogs
226:Lipids
199:
164:
156:
116:
66:, and
162:S2CID
114:S2CID
197:PMID
154:PMID
189:doi
146:doi
106:doi
102:203
35:of
217::
195:.
185:14
183:.
160:.
152:.
142:15
140:.
126:^
112:.
100:.
86:^
62:,
203:.
191::
168:.
148::
120:.
108::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
